Convelo Therapeutics
Dr. Lang has extensive background in drug discovery and development of therapeutics for neurological diseases and injuries. Dr. Lang previously served as a scientist on the regenerative medicine team at Athersys focused on clinical advancement of its MultiStem system for ischemic stroke. Dr. Lang is a scientific founder of Nervgen and inventor of Intracellular Sigma Peptide, Dr. Lang received his B.S. in Biology from the University of Wisconsin-Madison and his PhD in Neurosciences from Case Western Reserve University.
Convelo Therapeutics
Convelo Therapeutics is developing a new class of medicines that unlock the regenerative capacity of the central nervous system. Convelo is pioneering approaches to regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases including multiple sclerosis, pediatric leukodystrophies, traumatic injury and age-related pathologies such as Alzheimer’s. Convelo has identified key biological targets and a pipeline of drug candidates to provide novel and meaningful solutions for patients and their families.